Question-based Drug Development for psilocybin - Authors' reply.
Carhart-Harris RL, Nutt DJ.
Lancet Psychiatry · letter · DOI 10.1016/s2215-0366(16)30217-6 PUBLICATION REGISTRY
Go to research.
Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.
Publikationer som ChEBI hänvisar till för psilocybin. Visa hela publikationsregistret
A publication hit is not a conclusion. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.
Publications in the selection
51 hitsPsilocybin with psychological support for treatment-resistant depression: an open-label feasibility study.
Carhart-Harris RL, Bolstridge M, Rucker J, Day CM, Erritzoe D, Kaelen M, Bloomfield M, Rickard JA, Forbes B, Feilding A, Taylor D, Pilling S, Curran VH, Nutt DJ.
Lancet Psychiatry · clinical trial; journal article · DOI 10.1016/s2215-0366(16)30065-7Enhanced repertoire of brain dynamical states during the psychedelic experience.
Tagliazucchi E, Carhart-Harris R, Leech R, Nutt D, Chialvo DR.
Hum Brain Mapp · research support, non-u.s. gov't; research-article; journal article · DOI 10.1002/hbm.22562The effects of psilocybin and MDMA on between-network resting state functional connectivity in healthy volunteers.
Roseman L, Leech R, Feilding A, Nutt DJ, Carhart-Harris RL.
Front Hum Neurosci · research-article; journal article · DOI 10.3389/fnhum.2014.00204The effect of psilocin on memory acquisition, retrieval, and consolidation in the rat.
Rambousek L, Palenicek T, Vales K, Stuchlik A.
Front Behav Neurosci · research-article; journal article · DOI 10.3389/fnbeh.2014.00180Psilocybin-Induced Decrease in Amygdala Reactivity Correlates with Enhanced Positive Mood in Healthy Volunteers.
Kraehenmann R, Preller KH, Scheidegger M, Pokorny T, Bosch OG, Seifritz E, Vollenweider FX.
Biol Psychiatry · research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.1016/j.biopsych.2014.04.010Potential therapeutic effects of psilocybin/psilocin are minimized while possible adverse reactions are overrated.
dos Santos RG.
Ther Drug Monit · letter; comment · DOI 10.1097/ftd.0000000000000028Psilocybin--summary of knowledge and new perspectives.
Tylš F, Páleníček T, Horáček J.
Eur Neuropsychopharmacol · research support, non-u.s. gov't; review; journal article · DOI 10.1016/j.euroneuro.2013.12.006[The impact of psilocybin on visual perception and spatial orientation--neuropsychological approach].
Jastrzebski M, Bala A.
Psychiatr Pol · review; journal articleSpatiotemporal brain dynamics of emotional face processing modulations induced by the serotonin 1A/2A receptor agonist psilocybin.
Bernasconi F, Schmidt A, Pokorny T, Kometer M, Seifritz E, Vollenweider FX.
Cereb Cortex · research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.1093/cercor/bht178Activation of serotonin 2A receptors underlies the psilocybin-induced effects on α oscillations, N170 visual-evoked potentials, and visual hallucinations.
Kometer M, Schmidt A, Jäncke L, Vollenweider FX.
J Neurosci · research support, non-u.s. gov't; research-article; randomized controlled trial; journal article · DOI 10.1523/jneurosci.3007-12.2013Evolution of the toxins muscarine and psilocybin in a family of mushroom-forming fungi.
Kosentka P, Sprague SL, Ryberg M, Gartz J, May AL, Campagna SR, Matheny PB.
PLoS One · research support, non-u.s. gov't; research-article; review; research support, u.s. gov't, non-p.h.s.; journal article · DOI 10.1371/journal.pone.0064646Peak experiences of psilocybin users and non-users.
Cummins C, Lyke J.
J Psychoactive Drugs · journal article · DOI 10.1080/02791072.2013.785855Single treatments that have lasting effects: some thoughts on the antidepressant effects of ketamine and botulinum toxin and the anxiolytic effect of psilocybin.
Young SN.
J Psychiatry Neurosci · article-commentary; review; journal article · DOI 10.1503/jpn.120128Studying the effects of classic hallucinogens in the treatment of alcoholism: rationale, methodology, and current research with psilocybin.
Bogenschutz MP.
Curr Drug Abuse Rev · research support, non-u.s. gov't; review; journal article · DOI 10.2174/15733998113099990002Functional connectivity measures after psilocybin inform a novel hypothesis of early psychosis.
Carhart-Harris RL, Leech R, Erritzoe D, Williams TM, Stone JM, Evans J, Sharp DJ, Feilding A, Wise RG, Nutt DJ.
Schizophr Bull · research support, non-u.s. gov't; research-article; journal article · DOI 10.1093/schbul/sbs117Magic truffles or Philosopher's stones: a legal way to sell psilocybin?
Pellegrini M, Rotolo MC, Marchei E, Pacifici R, Saggio F, Pichini S.
Drug Test Anal · evaluation study; journal article · DOI 10.1002/dta.1400The NMDA antagonist ketamine and the 5-HT agonist psilocybin produce dissociable effects on structural encoding of emotional face expressions.
Schmidt A, Kometer M, Bachmann R, Seifritz E, Vollenweider F.
Psychopharmacology (Berl) · comparative study; research support, non-u.s. gov't; journal article · DOI 10.1007/s00213-012-2811-0Psilocybin links binocular rivalry switch rate to attention and subjective arousal levels in humans.
Carter OL, Hasler F, Pettigrew JD, Wallis GM, Liu GB, Vollenweider FX.
Psychopharmacology (Berl) · research support, non-u.s. gov't; journal article · DOI 10.1007/s00213-007-0930-9The pharmacology of psilocybin.
Passie T, Seifert J, Schneider U, Emrich HM.
Addict Biol · review; journal article · DOI 10.1080/1355621021000005937Experimental psychiatry. V. Psilocybine, a new psychotogenic drug.
RINKEL M, ATWELL CR, DIMASCIO A, BROWN J.
N Engl J Med · journal article · DOI 10.1056/nejm196002112620606